Abstract & Details
Description
Award ID: 2213051
The broader impact/commercial potential of this Small Business Innovation Research Phase II project is to develop a mature, market-ready approach for building targeted, readily synthesizable inhibitors of viral proteases. The technology will extend the discovery platform to new targets and disease indications and build a biochemical foundation for progressing preclinical programs to promising leads, starting with a potent lead candidate for treating COVID-19. The project seeks to generate new intellectual property that covers the discovery platform and promising small molecules, and it will support new opportunities to partner with pharmaceutical companies on antiviral therapeutics, which continue to be an important unmet medical need. This Small Business Innovation Research Phase II project seeks to expand and industrialize the companys recently demonstrated approach for using microbial systems to guide the discovery and assembly of protease inhibitors. The project focuses on COVID-19 and other viral diseases that lack effective treatments, exhibit significant epidemic potential, and/or remain relevant to U.S. biodefense. The research program may uncover inhibitors of a broad set of viral proteases and as it screens large libraries of biosynthetic pathways for targeted inhibitors. This solution complements the multi-part effort by developing a potent lead candidate for treating COVID-19 and a general workflow for the (bio)synthetic optimization of hits identified. Success in these tasks may stretch contemporary approaches to synthetic biology by applying them to the discovery and assembly of new biologically active compounds and may develop a supporting (bio)synthetic workflowone that that combines applied enzymology and synthetic chemistry. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
NSF Program Director: Erik Pierstorff
The broader impact/commercial potential of this Small Business Innovation Research Phase II project is to develop a mature, market-ready approach for building targeted, readily synthesizable inhibitors of viral proteases. The technology will extend the discovery platform to new targets and disease indications and build a biochemical foundation for progressing preclinical programs to promising leads, starting with a potent lead candidate for treating COVID-19. The project seeks to generate new intellectual property that covers the discovery platform and promising small molecules, and it will support new opportunities to partner with pharmaceutical companies on antiviral therapeutics, which continue to be an important unmet medical need. This Small Business Innovation Research Phase II project seeks to expand and industrialize the companys recently demonstrated approach for using microbial systems to guide the discovery and assembly of protease inhibitors. The project focuses on COVID-19 and other viral diseases that lack effective treatments, exhibit significant epidemic potential, and/or remain relevant to U.S. biodefense. The research program may uncover inhibitors of a broad set of viral proteases and as it screens large libraries of biosynthetic pathways for targeted inhibitors. This solution complements the multi-part effort by developing a potent lead candidate for treating COVID-19 and a general workflow for the (bio)synthetic optimization of hits identified. Success in these tasks may stretch contemporary approaches to synthetic biology by applying them to the discovery and assembly of new biologically active compounds and may develop a supporting (bio)synthetic workflowone that that combines applied enzymology and synthetic chemistry. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
NSF Program Director: Erik Pierstorff
| Status | Closed |
|---|---|
| Effective start/end date | 12/01/22 → 11/30/24 |
Funding
- SBIR Phase II: $1,000,000.00
Active Fiscal Year
- FY2024
- FY2023
- FY2025
Start Fiscal Year
- FY2023
TIP Programs
- SBIR Phase II
Small Business
- Yes
Key Technology Areas
- Biotechnology
- (confidence score: 100%)
- Disaster Prevention and Mitigation
- (confidence score: 100%)
Technology Foci
- Synthetic Biology
- (confidence score: 100%)
- Biotechnology - Other than SynBio
- (confidence score: 100%)
- Genomics and bioinformatics
- (confidence score: 100%)
- Pandemic prevention and response
- (confidence score: 90%)
Congressional District at Award
- District n. 02 of Colorado
Current Congressional District
- District n. 02 of Colorado
United States
- Colorado
Core Based Statistical Area (CBSA)
- Boulder, CO
County
- County: Boulder, CO
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint. Learn more about Elsevier's Fingerprint Engine here: https://beta.elsevier.com/products/elsevier-fingerprint-engine